Iron III isomaltose induced hypersensitivity reaction

Iron isomaltose is considered as safe form of iron with no test dose recommended. Here, we are describing the case of a patient who experienced allergic reaction with this formulation of iron. A 35-year-old South Asian woman experienced allergic reaction, she had mild wheeze on examination of chest. She was given intranasal oxygen at 2 L/min. She was given intravenous acetaminophen 1 g for pain relief, 45.4 mg intravenous chlorphenaramine and intravenous 100 mg hydrocortisone. Within half an hour, all her symptoms improved and her hypoxia resolved. Her chest wheezing also disappeared. Iron isomaltose, although relatively safe, can cause allergic reaction. Intravenous iron can cause allergic reaction therefore it should be administered at the facility where trained staff is present so that necessary treatment can be given in case of hypersensitivity reaction

To assess the aggressiveness of oral squamous cell carcinoma in the young population

Introduction: Squamous cell carcinoma of the oral cavity has a high prevalence not only worldwide but also in Asian countries. It has been estimated that the mortality from the tumor has remained almost 56% and cancer presenting at a younger age tends to be more aggressive and advance at the time of presentation. Objectives: To assess the pattern of recurrence and disease-free survival in two age groups. Materials and methods: This is a retrospective, cohort study of patients diagnosed with oral squamous cell carcinoma admitted between 2008 to 2018. Two groups were made with 40 years as a cut off mean. Various etiological factors, staging, treatment, site of the tumor, and recurrence and mortality were assessed. Results: Patients who underwent treatment for the cancer of which 124 patients were of less than 40 years and 327 were of age above 40 years. The ratio between males to females in Age40 was 3:1 respectively. The most common site of the tumor is cheek in origin. Patients in Age 40 years recurrence of tumor is (n=120, 37%) with CI of 95% (P=0.653) and the overall mortality in Age40 (n=168, 51%) of patients have a mortality with CI of 95% (P=0.811). Conclusion: Overall the study suggests that mortality of the tumor is almost the same with a slight difference in recurrence of the disease. Cheek is the most common site of presentation